The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab—Polish Experiences

Biosimilars are cheaper than original drugs and are thus of interest to the public. The aim of this article is to assess the benefits of introducing more than one biosimilar for the same substance (active pharmaceutical ingredient, API). The hypothesis is that the introduction of successive biosimil...

Descripción completa

Detalles Bibliográficos
Autores principales: Barszczewska, Olga, Piechota, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297232/
https://www.ncbi.nlm.nih.gov/pubmed/34209612
http://dx.doi.org/10.3390/ijerph18136952

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297232/
https://www.ncbi.nlm.nih.gov/pubmed/34209612
http://dx.doi.org/10.3390/ijerph18136952

Ejemplares similares